NCT06205628View on ClinicalTrials.gov

Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension

PHASE1RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 21, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

September 30, 2026

Conditions
HypertensionHypertension,Essential
Interventions
DRUG

ADX-850

siRNA duplex oligonucleotide

DRUG

Placebo

Saline

Trial Locations (3)

5000

RECRUITING

CMAX Clinical Research, Adelaide

6009

RECRUITING

Linear Clinical Research, Nedlands

Unknown

RECRUITING

Clinitrials Pty Ltd, Perth

Sponsors

Collaborators (1)

Avance Clinical Pty Ltd.
All Listed Sponsors
collaborator

ADARx Australia Pty Ltd

UNKNOWN

collaborator

Avance Clinical Pty Ltd.

INDUSTRY

lead

ADARx Pharmaceuticals, Inc.

INDUSTRY